AstraZeneca partners with VaxEquity on self-amplifying RNA therapeutics
AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform. VaxEquity was founded last year by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.